scholarly journals EVALUASI ANALITIK POCT METODE GLUCOSE DEHYDROGENASE PARAMETER GLUKOSA PADA SPESEIMEN SERUM DAN PLASMA EDTA

2021 ◽  
Vol 9 (1) ◽  
pp. 26-36
Author(s):  
Suryanata Kesuma ◽  
Didi Irwadi ◽  
Nia Ardelia

Diabetes is a non-communicable disease that can be prevented and detected as early as possible by routine glucose checks. Point Of Care Testing (POCT) as a diabetes test screening tool is widely used by health care institutions and is even used independently by the wider community. Blood glucose can be measured by serum, plasma, and whole blood specimens. The standard specimen for glucose measurement using POCT is whole blood. Based on the author's survey, the use of the POCT tool in several health care institutions was not following the insert of the tool kit, one of which was the type of specimen used. Many laboratories use EDTA serum and plasma specimens for glucose testing using the POCT device. There are many methods used in the POCT tool, one of these methods is the glucose dehydrogenase method. Therefore analytic evaluation is necessary to ensure the accuracy and accuracy of laboratory examination results in glucose examination. This type of research is the analytical method with a comparative design. The data was collected using the total sampling method. The data is reported using Microsoft Excel and SPSS applications. The number of samples for analytic evaluation was 40 samples. Based on the results of tests performed in duplicate, there were clinical differences in glucose values using serum and plasma EDTA samples so that the use of these samples was not suitable for use for diagnostic purposes using the POCT glucose dehydrogenase method. There was a statistical difference in serum glucose and plasma EDTA against whole blood that was examined using the POCT glucose dehydrogenase method with a correlation value (R) of 0.9722 and 0.9695.

2021 ◽  
pp. 104063872110197
Author(s):  
Natalie D. Suchowersky ◽  
Elizabeth A. Carlson ◽  
Hollie P. Lee ◽  
Ellen N. Behrend

Previous studies have determined that, compared to whole blood, serum or plasma used in a portable blood glucometer (PBG) may provide more accurate results. We investigated the accuracy of a veterinary PBG (AlphaTRAK 2; Zoetis) for the measurement of glucose concentrations in serum, plasma, and whole blood compared to plasma glucose concentration measured by a biochemical analyzer. Blood samples from 53 client-owned dogs were collected. Lin concordance correlation coefficient (ρc) and Bland–Altman plots were used to determine correlation and agreement between the results obtained for the different sample types. Glucose concentration in whole blood measured by the veterinary PBG was more strongly correlated with the glucose concentration measured by the biochemical analyzer (ρc = 0.92) compared to plasma and serum glucose concentrations (ρc = 0.59 and 0.57, respectively). The mean differences between the glucose concentrations in whole blood, plasma, and serum measured by the veterinary PBG and the glucose concentration determined by the biochemical analyzer were 1.0, 6.3, and 6.7 mmol/L (18, 113, and 121 mg/dL), respectively. Our findings suggest that, when using this veterinary PBG, the accuracy of a glucose measurement obtained is higher when using whole blood compared to plasma or serum. Use of whole blood allows for more correct assessment and diagnosis, which are necessary for appropriate therapeutic intervention.


2012 ◽  
Vol 6 (3) ◽  
pp. 232-240 ◽  
Author(s):  
Richard F. Louie ◽  
William J. Ferguson ◽  
Stephanie L. Sumner ◽  
Jimmy N. Yu ◽  
Corbin M. Curtis ◽  
...  

ABSTRACTObjective: To characterize the performance of glucose meter test strips using simulated dynamic temperature and humidity disaster conditions.Methods: Glucose oxidase- and glucose dehydrogenase-based test strips were dynamically stressed for up to 680 hours using an environmental chamber to simulate conditions during Hurricane Katrina. Paired measurements vs control were obtained using 3 aqueous reagent levels for GMS1 and 2 for GMS2.Results: Stress affected the performance of GMS1 at level 1 (P <. 01); and GMS2 at both levels (P <. 001), lowering GMS1 results but elevating GMS2 results. Glucose median-paired differences were elevated at both levels on GMS2 after 72 hours. Median-paired differences (stress minus control) were as much as −10 mg/dL (range, −65 to 33) at level 3 with GMS1, with errors as large as 21.9%. Glucose median-paired differences were as high as 5 mg/dL (range, −1 to 10) for level 1 on GMS2, with absolute errors up to 24.4%.Conclusions: The duration of dynamic stress affected the performance of both GMS1 and GMS2 glucose test strips. Therefore, proper monitoring, handling, and storage of point-of-care (POC) reagents are needed to ensure their integrity and quality of actionable results, thereby minimizing treatment errors in emergency and disaster settings.(Disaster Med Public Health Preparedness. 2012;6:232–240)


1992 ◽  
Vol 38 (8) ◽  
pp. 1479-1482 ◽  
Author(s):  
L Ashworth ◽  
I Gibb ◽  
K G Alberti

Abstract We assessed the HemoCue system for measuring glucose in 5 microL of whole blood. A glucose dehydrogenase-based reaction is used with dried reagents contained in disposable microcuvettes, which are filled with blood by capillary action. Automated hexokinase and YSI 23AM glucose analyzer methods were used for comparison. Overall imprecision (CV) was better than 4.5%, with no significant differences in results between three different HemoCue photometers and four batches of microcuvettes. Regression slopes (+/- SE) were 0.947 (0.011) with the YSI and 0.966 (0.015) with the hexokinase method. Analytical recovery of added glucose was 101-106%, and the system functioned with hematocrits up to 0.65. Bilirubin up to 453 mumol/L did not interfere, but high concentrations of endogenous (greater than 3 mmol/L) and exogenous triglycerides gave positive interference. The system proved stable and robust under a wide range of storage and handling conditions; performance was impaired only at high ambient temperature (37 degrees C). We conclude that the HemoCue system should prove useful for glucose measurement; further testing outside the laboratory is warranted.


2007 ◽  
Vol 1 (1) ◽  
pp. 26-30 ◽  
Author(s):  
Hideaki Yamaoka ◽  
Koji Sode

We report here the development of a novel disposable-type glucose enzyme sensor based on a screen-printed carbon electrode (SPCE) employing a catalytic subunit of FAD-dependent glucose dehydrogenase (FADGDH) and a Rucomplex (hexaammineruthenium (III) chloride) as the electron mediator. The whole blood glucose measurement was achieved in 2 seconds using a 500 nl sample of the range of 100-800 mg/ml.


2018 ◽  
Vol 58 (2) ◽  
pp. 146-150 ◽  
Author(s):  
Ayush Gupta ◽  
William Bonadio

We aimed to determine the frequency of blood glucose and electrocardiogram (EKG) abnormalities in previously healthy children who present to an emergency department (ED) with a diagnosis of benign syncope. Chart review of consecutive children aged 5 to 18 years presenting to the pediatric ED from 2004 to 2014 with a discharge diagnosis of benign syncope was done. Of 969 patients, hypoglycemia (serum glucose <60 mg/dL) was present in only 3 cases (0.3%). Of 754 patients with EKG performed, only 4 cases (0.6%) was an abnormality requiring further cardiac evaluation identified; cardiac echocardiogram was performed in 3 of these 4 patients, which revealed no cardiac pathology. Financial analysis for performing blood glucose measurement and EKG on these patients amounted to total health care cost of $222 526. We concluded that previously healthy children with syncope rarely have hypoglycemia or underlying cardiac abnormality. The routine performance of tests can incur significant health care expenditure.


2016 ◽  
Vol 54 (8) ◽  
pp. 2104-2108 ◽  
Author(s):  
Ilesh V. Jani ◽  
Bindiya Meggi ◽  
Adolfo Vubil ◽  
Nádia E. Sitoe ◽  
Nilesh Bhatt ◽  
...  

Viral load testing is the WHO-recommended monitoring assay for patients on HIV antiretroviral therapy (ART). Point-of-care (POC) assays may help improve access to viral load testing in resource-limited settings. We compared the performance of the Alere Q NAT POC viral load technology (Alere Technologies, Jena, Germany), measuring total HIV RNA using finger prick capillary whole-blood samples collected in a periurban health center, with that of a laboratory-based plasma RNA test (Roche Cobas Ampliprep/Cobas TaqMan v2) conducted on matched venous blood samples. The whole-blood Alere Q NAT POC assay produced results with a bias of 0.8593 log copy/ml compared to the laboratory-based plasma assay. However, at above 10,000 copies/ml, the bias was 0.07 log copy/ml. Using the WHO-recommended threshold to determine ART failure of 1,000 copies/ml, the sensitivity and specificity of the whole-blood Alere Q NAT POC assay were 96.83% and 47.80%, respectively. A cutoff of 10,000 copies/ml of whole blood with the Alere Q NAT POC assay appears to be a better predictor of ART failure threshold (1,000 copies/ml of plasma), with a sensitivity of 84.0% and specificity of 90.3%. The precision of the whole-blood Alere Q NAT POC assay was comparable to that observed with the laboratory technology (5.4% versus 7.5%) between detectable paired samples. HIV POC viral load testing is feasible at the primary health care level. Further research on the value of whole-blood viral load to monitor antiretroviral therapy is warranted.


2020 ◽  
Vol 44 (2) ◽  
pp. 97-102 ◽  
Author(s):  
Alexander von Meyer ◽  
Peter B. Luppa ◽  
Janne Cadamuro

AbstractBackgroundQuality assurance (QA) in point-of-care testing (POCT) is an important issue for organizing POCT structures within the healthcare sector. In Germany, only one device needs to participate in an external QA program, if the responsible core laboratory is supervising internal quality controls of all other identical POCT devices. This flexible definition of quality control (QC) testing is in line with the fundamentals of ISO 22870 and the ISO 15189, but can only be regarded as a minimum requirement.MethodsWe present a pilot study for an inexpensive new approach for additional POCT QC measurement similar to the external QA program within the medical laboratory using capillary glucose measurement as an example. This new system, referred to as “extended internal QC (eIQC)”, uses in-house generated QC material from leftover full blood from routine diagnostics. We provide information on calculation of target values and acceptance ranges and preliminary data on stability and comparison between POCT and core laboratory testing (COBAS 8000). Additionally, we simulated the approach using three devices within the laboratory as surrogate for three POCT sites. In this pilot study, measurements of QC material beyond the mandatory QA plan are structured and optimized through the use of the POCTopus Software solution.ResultsQC material was easily generated including specification of target values. The software aided in automatized processing of the samples. The software showed limitations in evaluation and monitoring without relevant use of resources. We found a significant bias between measurements on POCT and COBAS 8000 instruments.ConclusionsThe presented new approach for additional QAs for POCT enables POCT coordinators to establish an additional safety and QC level. Further software improvements are required. Further studies are needed for validation and comparison measurements between methods. Overall, this approach offers great potential for POCT structures seeking higher quality standards.


Sign in / Sign up

Export Citation Format

Share Document